1.Nrf2: a new target for nonalcoholic fatty liver disease
Acta Pharmaceutica Sinica 2022;57(11):3268-3275
The liver is an important organ of the body, which has many functions, such as metabolism and detoxification. Due to the rapid change of lifestyle and the improvement of public health, the incidence rate of non-communicable diseases has increased significantly, which fundamentally changed the disease characteristics in most parts of the world. At present, the global prevalence of non-alcoholic fatty liver disease (NAFLD) is about 25%. Moreover, about 59.10% of NAFLD patients progress to non-alcoholic steatohepatitis (NASH) within 5 years, and about 41% of NASH patients progress to fibrosis. NAFLD has become one of the most important liver diseases in the world and may become the main cause of end-stage liver disease in the next few decades. In addition, NAFLD and related cirrhosis will bring huge economic burden to patients, health care system and society. Since there are currently no medications available that have been approved by Food and Drug Administration (FDA), NAFLD is still treated mainly through lifestyle changes such as exercise and diet. Oxidative stress and inflammation are the most important pathological processes in the occurrence and development of liver diseases. Nuclear factor erythroid-2-related factor 2 (Nrf2) is a key regulator of the body's antioxidant stress system, with anti-inflammatory, antioxidant and other functions. Many studies have shown that Nrf2 pathway significantly affects the progression of liver diseases. In this review, we aimed to summarize the regulatory role of the Kelch-like ECH-associating protein 1 (Keap1)-Nrf2-antioxidant response element (ARE) signaling pathway in the pathogenesis of NAFLD, and to reveal the potential of Nrf2 as a therapeutic target for NAFLD.
2.Effect of Budesonide on Dendritic Cells in Asthmatic Mice
Journal of Applied Clinical Pediatrics 2006;0(16):-
Objective To explore the effect of budesonide(BUD) on dendritic cell(DC) and airway inflammation in the asthmatic mice.Methods Forty female Kunming mice were divided into 4 groups:asthmatic model group,therapeutic control group,BUD treated group,and normal control group,with 10 mice in each group.Mice were sensitized by an intraperitoneal injection of 50 ?g ovalbumin(OVA) adsorbed to 1 mg aluminum hydroxide dissolved in 0.2 mL saline.Animals were boosted on the 14th day in the same way.From the 21th to 35th days,and mice were challenged with 10 g/L aerosolized OVA for 30 min a day to establish a murine model of asthma.To evaluate the effect of BUD,60 minutes prior to OVA exposure,the mice were treated with 1 mg aerosolized BUD or placebo(saline).Control animals were sensitized intraperitoneally with saline and challenged with aerosolized saline alone.Eosinophil(EOS) count,degree of mucus secretion and DC count around the airways were measured by haematoxylin and eosin staining,periodic acid schiff's staining,immunochemistry technique and computerized image analysis system.Results In asthmatic model group,EOS count,DC count and the degree of mucus secretion around the airways were increased compared with nomal control group(P_a0.05).In BUD treated group,EOS count,DC count and the degree of mucus secretion around the airways were decreased compared with the asthmatic model group(P_a
3.Preterm Rupture of Fetal Membranes and Neonatal Respiratory Distress Syndrome in Premature Infants
zhi-wei, LIU ; yue-hua, SHEN ; qing-sheng, CHEN
Journal of Applied Clinical Pediatrics 1992;0(06):-
24 hours) and versus control group(
5.Expression of 3 markers and its correlation with prognosis of patients with non-small cell lung cancer
Penghua WEI ; Zhipeng SHEN ; Hua WANG ; Suquan QIAN ; Zhi GAO
International Journal of Laboratory Medicine 2017;38(16):2243-2245,2248
Objective To investigate the expressions of ALCAM,IL-17RA and PIK3CA in patients with non-small cell lung cancer,and to investigate the correlation between the above-mentioned indexes and patients′ prognosis.Methods A total of 65 patients with non-small cell lung cancer admitted to the third People′s Hospital in Liaocheng City were selected and were served as study objects.Immunohistochemical staining(S-P) method was used to detect the expression of ALCAM,IL-17RA and PIK3CA in tissues to analyze the difference of expression between different pathological parameters.And 65 patients were followed up after the operation to compare the survival time of patients in the negative expression group and the positive expression group,and to analyze the correlation between ALCAM,IL-17RA and PIK3CA and the prognosis of the disease.Results Among the 65 cases of patients,47 cases were positive for ALCAM with the positive rate of 72.3%,34 cases were positive for IL-17RA with the positive rate of 52.3%;31 cases were positive for PIK3CA with the positive rate of 47.7%.There was significant difference in the expression of ALCAM,IL-17RA and PIK3CA in patients with different pathological types,TNM staging and lymph node metastasis(P<0.05).There was no significant statistical difference in the expression of patients with different genders and ages(P>0.05).The median survival time of patients with positive results of ALCAM,IL-17RA and PIK3CA were lower than those of negative group,and the differences were statistically significant(P<0.05).Conclusion The expression of ALCAM,IL-17RA and PIK3CA increased in non-small cell lung cancer tissues to remind the higher degree of malignancy and poor prognosis.
6.Roles of Th_1/Th_2 type cytokines in experimental autoimmune neuritis
Yun WU ; Hua-Bing WANG ; Wei-Zhi WANG ;
Chinese Journal of Neurology 2005;0(09):-
Objective To establish the model of P2 peptide-induced experimental autoimmune neuritis(EAN)in rats and explore the roles of Th_1/Th_2 type eytokines in EAN.Methods Lewis rats were grouped into EAN rats and control rats.The EAN rats were immunized by injection into both hind footpads of inoculums containing 100 ?g or 200 ?g of P2_(57-81)peptide and FCA while the control rats were immunized with FCA only.Clinical scores were compared at the maximum of disease.Supernatant productions of IFN- ?, IL-4 and IL-10 secreted by lymphocytes and obtained on day 14 after the immunization were examined. Histopathological assessment of sciatic nerves was made.Results Peak clinical scores of P2_(57-81)200 ?g (3.6?0.3)group were significantly higher than P2_(57-81)100 ?g group(2.2?0.6,P
7.Effect of SMO preservation solution on apoptosis and energy metabolism in canine kidneys during cold storage
Qiu-Cheng HAN ; Xiong-Wei ZHU ; Zhi-Hua ZHOU ;
Chinese Journal of Organ Transplantation 2005;0(10):-
0.05).The activity of Na~+-K~+ ATPase in SMO group was significantly higher than that in HTK group at 72 h(P
9.Total cyst extirpation for the treatment of hepatic cystic echinococcosis
Zhi-hua YEXIE ; Gang WU ; Wei-fan XIN ;
Chinese Journal of General Surgery 2008;23(4):276-278
Objective To investigate the effect of radical surgical excision of total cyst for hepatic cystic echinoccosis. Methods During six years,86 patients with hepatic cystic echinococcosis were treated by radical surgical excision of the total cyst.Hospital stay,abdominal drainage time,residual cavity drainage,accumulated liquid in residual cavity,residual cavity infection and recurrence were compared with that in 90 cases receiving internal capsule extirpation. Results Radical surgical excision of total cyst for hepatic cystic echinococcosis is safe and very effective,the average hospital stay was significant shorter(P<0.001)and there was no significant complications such as billiay fistula,residual cavity infection,accumulated liquid of residual cavity and recurrence of hydatid cyst. Conclusion Radical surgical excision of total cyst is an ideal and new therapeutic method for the treatment of hepatic cystic eehinococcosis.
10.Etanercept combined with Tripterygium wilfordii polyglycoside for treatment of rheumatoid arthritis in the elderly: a clinical study.
Wei-Zhen HE ; Zhi-Hua YIN ; Jian-Hua GAO ; Zhi-Zhong YE ; Yan XIE ; Wei-Hong KONG ; Ya-Shuo CHEN
Chinese Journal of Integrated Traditional and Western Medicine 2014;34(3):267-271
OBJECTIVETo evaluate the efficacy and safety of etanercept plus Tripterygium wilfordii polyglycoside (TWP) in elderly patients with active rheumatoid arthritis (RA).
METHODSTotally 46 elderly patients with active RA were randomly assigned to the treatment group (22 cases) and the control group (24 cases). All patients received subcutaneous injection of etanercept, 25 mg each time, twice per week. The dosage was reduced to once per week 3 months later. Patients in the treatment group took TWP Tablet (10 mg each time, three times per day), while those in the control group took methotrexate (MTX), 10 mg each time, once per week. The whole course lasted for 24 weeks. Patients' rest pain, tender joint number, swollen joint number, health assessment questionnaire (HAQ), patients' global assessment, physicians' global assessment, erythrocyte sediment rate (ESR), C reactive protein (CRP), rheumatic factor were assessed at week 0, 4, 8, 12, and 24. The curative effect was statistically evaluated by the United States Institute of Rheumatology ACR20, ACR50, and ACR70 improvement criteria. Meanwhile, any adverse event was recorded and evaluated.
RESULTSTotally 41 completed the trial, and 5 dropped off (3 in the treatment group and 2 in the control group). Compared with the control group, there was no statistical difference in ACR20, ACR50, or ACR70 in the treatment group (P > 0.05). Compared with before treatment in the same group, there was some improvement in tender joint number, swollen joint number, visual analogue scale (VAS) for patients' global assessment, VAS for physicians' global assessment, ESR, CRP, and HAQ between the two groups, showing statistical difference (P < 0.05). Compared with the control group in the same phase, there was no statistical difference in the treatment group (P > 0.05). There was no statistical difference in the occurrence of adverse events between the two groups.
CONCLUSIONSEtanercept plus TWP could achieve equivalent therapeutic effect to that of Etanercept plus MTX. The two regimens could improve clinical signs, symptoms, and QOL related to RA. They were well tolerated in the treatment of elderly patients with active RA.
Aged ; Antirheumatic Agents ; therapeutic use ; Arthritis, Rheumatoid ; drug therapy ; Drug Therapy, Combination ; Etanercept ; Female ; Glycosides ; therapeutic use ; Humans ; Immunoglobulin G ; therapeutic use ; Male ; Middle Aged ; Receptors, Tumor Necrosis Factor ; therapeutic use ; Treatment Outcome ; Tripterygium ; chemistry